DRAHT MEDICAL

The team behind DRAHT has pinpointed significant advancements in the delivery of Transcatheter Aortic Valve (TAVR) implants. Leveraging insights gleaned from over 2,000 TAVR procedures and extensive consultations with implanting cardiologists, DRAHT has identified and tested five key areas of intellectual property that tackle these challenges head-on. While the primary focus remains on TAVR indications and launch, the technology holds promise for a broader spectrum of emergent structural heart procedures as well as applications in Renal Denervation, Critical Limb Ischemia, and Cardiac Ablation for the treatment of Atrial Fibrillation. Though the design provides vastly improved procedural functionality, it subsequently provides the clinical benefits of real-time intra-procedural feedback of multiple data points, and opportunity to integrate data with DICOM formats for the collection of RWE.

• Employees 1
• Founded 2022